Maze Therapeutics, Common Stock Market Value
| MAZE Stock | 42.10 0.02 0.05% |
| Symbol | Maze |
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Maze Therapeutics,. If investors know Maze will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Maze Therapeutics, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Maze Therapeutics, Common is measured differently than its book value, which is the value of Maze that is recorded on the company's balance sheet. Investors also form their own opinion of Maze Therapeutics,'s value that differs from its market value or its book value, called intrinsic value, which is Maze Therapeutics,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Maze Therapeutics,'s market value can be influenced by many factors that don't directly affect Maze Therapeutics,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Maze Therapeutics,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Maze Therapeutics, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Maze Therapeutics,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Maze Therapeutics, 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Maze Therapeutics,'s stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Maze Therapeutics,.
| 11/28/2025 |
| 12/28/2025 |
If you would invest 0.00 in Maze Therapeutics, on November 28, 2025 and sell it all today you would earn a total of 0.00 from holding Maze Therapeutics, Common or generate 0.0% return on investment in Maze Therapeutics, over 30 days. Maze Therapeutics, is related to or competes with Zymeworks Common, Pharvaris, Immunome, Spyre Therapeutics, Sionna Therapeutics,, Intellia Therapeutics, and Wave Life. More
Maze Therapeutics, Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Maze Therapeutics,'s stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Maze Therapeutics, Common upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 2.74 | |||
| Information Ratio | 0.239 | |||
| Maximum Drawdown | 16.6 | |||
| Value At Risk | (4.62) | |||
| Potential Upside | 6.61 |
Maze Therapeutics, Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Maze Therapeutics,'s investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Maze Therapeutics,'s standard deviation. In reality, there are many statistical measures that can use Maze Therapeutics, historical prices to predict the future Maze Therapeutics,'s volatility.| Risk Adjusted Performance | 0.194 | |||
| Jensen Alpha | 0.8184 | |||
| Total Risk Alpha | 0.4998 | |||
| Sortino Ratio | 0.2809 | |||
| Treynor Ratio | 2.36 |
Maze Therapeutics, Common Backtested Returns
Maze Therapeutics, appears to be very steady, given 3 months investment horizon. Maze Therapeutics, Common has Sharpe Ratio of 0.27, which conveys that the firm had a 0.27 % return per unit of risk over the last 3 months. By analyzing Maze Therapeutics,'s technical indicators, you can evaluate if the expected return of 0.86% is justified by implied risk. Please exercise Maze Therapeutics,'s Risk Adjusted Performance of 0.194, mean deviation of 2.46, and Downside Deviation of 2.74 to check out if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Maze Therapeutics, holds a performance score of 21. The company secures a Beta (Market Risk) of 0.36, which conveys possible diversification benefits within a given portfolio. As returns on the market increase, Maze Therapeutics,'s returns are expected to increase less than the market. However, during the bear market, the loss of holding Maze Therapeutics, is expected to be smaller as well. Please check Maze Therapeutics,'s kurtosis, and the relationship between the downside variance and day median price , to make a quick decision on whether Maze Therapeutics,'s current price movements will revert.
Auto-correlation | 0.66 |
Good predictability
Maze Therapeutics, Common has good predictability. Overlapping area represents the amount of predictability between Maze Therapeutics, time series from 28th of November 2025 to 13th of December 2025 and 13th of December 2025 to 28th of December 2025. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Maze Therapeutics, Common price movement. The serial correlation of 0.66 indicates that around 66.0% of current Maze Therapeutics, price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.66 | |
| Spearman Rank Test | 0.38 | |
| Residual Average | 0.0 | |
| Price Variance | 1.55 |
Maze Therapeutics, Common lagged returns against current returns
Autocorrelation, which is Maze Therapeutics, stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting Maze Therapeutics,'s stock expected returns. We can calculate the autocorrelation of Maze Therapeutics, returns to help us make a trade decision. For example, suppose you find that Maze Therapeutics, has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
Maze Therapeutics, regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If Maze Therapeutics, stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if Maze Therapeutics, stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in Maze Therapeutics, stock over time.
Current vs Lagged Prices |
| Timeline |
Maze Therapeutics, Lagged Returns
When evaluating Maze Therapeutics,'s market value, investors can use the concept of autocorrelation to see how much of an impact past prices of Maze Therapeutics, stock have on its future price. Maze Therapeutics, autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, Maze Therapeutics, autocorrelation shows the relationship between Maze Therapeutics, stock current value and its past values and can show if there is a momentum factor associated with investing in Maze Therapeutics, Common.
Regressed Prices |
| Timeline |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Maze Therapeutics, Common is a strong investment it is important to analyze Maze Therapeutics,'s competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Maze Therapeutics,'s future performance. For an informed investment choice regarding Maze Stock, refer to the following important reports:Check out Maze Therapeutics, Correlation, Maze Therapeutics, Volatility and Maze Therapeutics, Alpha and Beta module to complement your research on Maze Therapeutics,. You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Maze Therapeutics, technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.